Scholarlink

<p>Artificial ovary (AO) construction is a promising approach for restoring fertility and endocrine function in patients with ovarian insufficiency caused by aging, gonadotoxic cancer treatments, or genetic and autoimmune disorders. Despite substantial experimental progress, the clinical readiness of available AO material platforms remains unclear. This review systematically evaluates biomaterials and construction strategies used in AO development, with emphasis on the relationship between material properties, biological performance, and translational potential. A total of 116 original studies published between 1990 and 2025 were analyzed using a tiered evidence framework (Tiers 0–5), ranging from material characterization to long-term endocrine restoration or live birth. Natural biomaterials generally support early follicular survival but are limited by mechanical instability and variability, whereas synthetic platforms offer improved reproducibility yet require biofunctionalization. Composite systems increasingly achieve advanced outcomes by addressing follicular expansion, vascularization, and immune compatibility. Key barriers to clinical translation include vascular integration, long-term function, GMP compliance, and regulatory feasibility. This review provides an evidence-based framework to guide clinically relevant AO development.</p> Graphical Abstract <p>Construction of artificial ovaries. 1. Selection and screening of materials with high biocompatibility; 2. Acquisition and isolation of follicles; 3. Encapsulation of follicles in biomaterials for culture; 4. Biomimetic regulation of the microenvironment; 5. In vivo transplantation and functional integration. Created in BioRender.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bioengineering strategies and material innovations for artificial ovary construction: progress, challenges, and future directions

  • 期刊论文

  • 发表日期：

    2026年4月16日

查看全文
  • Meng Yue Feng,
  • Min Jiang,
  • Yuan Yu,
  • Yu Lin Li,
  • Xin Liang

摘要

Artificial ovary (AO) construction is a promising approach for restoring fertility and endocrine function in patients with ovarian insufficiency caused by aging, gonadotoxic cancer treatments, or genetic and autoimmune disorders. Despite substantial experimental progress, the clinical readiness of available AO material platforms remains unclear. This review systematically evaluates biomaterials and construction strategies used in AO development, with emphasis on the relationship between material properties, biological performance, and translational potential. A total of 116 original studies published between 1990 and 2025 were analyzed using a tiered evidence framework (Tiers 0–5), ranging from material characterization to long-term endocrine restoration or live birth. Natural biomaterials generally support early follicular survival but are limited by mechanical instability and variability, whereas synthetic platforms offer improved reproducibility yet require biofunctionalization. Composite systems increasingly achieve advanced outcomes by addressing follicular expansion, vascularization, and immune compatibility. Key barriers to clinical translation include vascular integration, long-term function, GMP compliance, and regulatory feasibility. This review provides an evidence-based framework to guide clinically relevant AO development.

Graphical Abstract

Construction of artificial ovaries. 1. Selection and screening of materials with high biocompatibility; 2. Acquisition and isolation of follicles; 3. Encapsulation of follicles in biomaterials for culture; 4. Biomimetic regulation of the microenvironment; 5. In vivo transplantation and functional integration. Created in BioRender.